The authors would like to thank to Gareth Jones (Liverpool Reviews and Implementation Group) for administrative support and Eleanor Kotas (Liverpool Reviews and Implementation Group) for conducting the searches. The AG would also like to thank Dr Caroline Brammer (Consultant in Clinical Oncology, The Clatterbridge Cancer Centre) for reading and commenting on a draft of the report.
Contributions of authors
Nigel Fleeman (Research Fellow, University of Liverpool) reviewed the evidence for clinical effectiveness, including study selection, data extraction, synthesis and interpretation. He contributed to the study selection for inclusion into the cost-effectiveness review and provided editorial input.
Rachel Houten [Research Associate (Health Economics Modelling), University of Liverpool] reviewed the evidence for cost-effectiveness, including study selection, data extraction, synthesis and interpretation. She contributed to the study selection for inclusion into the clinical effectiveness review and developed cost models for routine treatment and AEs.
Adrian Bagust (Professor of Health Modelling, University of Liverpool) developed the de novo economic model.
Marty Richardson [Research Associate (Medical Statistician), University of Liverpool] provided statistical advice and quality assessment of the systematic reviews included in the clinical effectiveness review.
Sophie Beale [Research Associate (Decision Analyst), University of Liverpool] interpreted the clinical effectiveness and cost-effectiveness evidence, summarised the company economic models and provided editorial input.
Angela Boland (Associate Director, University of Liverpool) interpreted the clinical effectiveness and cost-effectiveness evidence and provided editorial input.
Yenal Dundar (Research Fellow, University of Liverpool) contributed to data extraction and the quality assessment of studies included in the clinical effectiveness review.
Janette Greenhalgh [Senior Research Fellow (Clinical Effectiveness), University of Liverpool] contributed to data extraction and the quality assessment of studies included in the clinical effectiveness review.
Juliet Hounsome (Research Associate, University of Liverpool) contributed to the protocol development and the selection of studies for inclusion into the clinical effectiveness review.
Rui Duarte (Health Technology Assessment Lead, University of Liverpool) provided editorial input.
Aditya Shenoy (Consultant in Clinical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust) provided clinical advice on all aspects of the review.
All authors contributed to the writing of the report.
Publication
Fleeman N, Houten R, Chaplin M, Beale S, Boland A, Dundar Y, et al. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer 2019;19;1209.
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to anonymised data may be granted following review.
Disclaimers
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.